Biopharma & Life Sciences
Spyre Therapeutics Executive Compensation (FY25)
SYRE · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Cameron Turtle | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Spyre Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (DEF 14A): April 10, 2026
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
150 figures on this page, cited to the filing that reported them. See the citations
More on Spyre Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Cameron Turtle: $6,960,186 → $6,707,361 (3.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Spyre Therapeutics' chief executive and what were they paid?
Total compensation for Cameron Turtle, Chief Executive Officer, came to $6,707,361 in fiscal 2025. Compared with the $6,960,186 reported for fiscal 2024, Turtle's total was 3.6% lower.
Which companies are in Spyre Therapeutics' peer group?
The disclosed peer group includes AnaptysBio, Inc., Apogee Therapeutics, Inc., Arcellx, Inc., Astria Therapeutics, Inc. and Celldex Therapeutics, Inc., among others.
What is Spyre Therapeutics' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 15:1, against median employee compensation of $437,242.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jeffrey Goldberg Former President and Chief Executive Officer | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Jonathan Alspaugh Former Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Cameron Turtle Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Jonathan Alspaugh Former Chief Financial Officer Departed during or after this year | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Scott Burrows Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Heidy King-Jones Chief Legal Officer and Corporate Secretary | ◇ | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey Goldberg Former President and Chief Executive Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sheldon Sloan Chief Medical Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Cameron Turtle Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Scott Burrows Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Heidy King-Jones Chief Legal Officer and Corporate Secretary | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Cameron Turtle Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Sheldon Sloan Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Heidy King-Jones Chief Legal Officer and Corporate Secretary | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Scott Burrows Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Cameron Turtle | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Heidy King-Jones | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Scott Burrows | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sheldon Sloan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Cameron Turtle | Option | ◇ | — | ◇ | 6/22/2033 |
| Option | ◇ | — | ◇ | 1/15/2035 | |
| Option | ◇ | — | ◇ | 11/22/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/1/2034 | |
| Sheldon Sloan | Option | ◇ | — | ◇ | 10/1/2034 |
| Option | ◇ | — | ◇ | 1/15/2035 | |
| Heidy King-Jones | Option | ◇ | — | ◇ | 9/1/2033 |
| Option | ◇ | — | ◇ | 1/15/2035 | |
| Option | ◇ | — | ◇ | 2/1/2034 | |
| Scott Burrows | Option | ◇ | — | ◇ | 9/1/2033 |
| Option | ◇ | — | ◇ | 1/15/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/1/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Jeffrey Albers | ◇ | — | ◇ | — | — | — | ◇ |
Laurie Stelzer | ◇ | — | ◇ | — | — | — | ◇ |
Sandra Milligan | ◇ | — | ◇ | — | — | — | ◇ |
Michael Henderson | ◇ | — | ◇ | — | — | — | ◇ |
Tomas Kiselak | ◇ | — | ◇ | — | — | — | ◇ |
Peter Harwin | ◇ | — | ◇ | — | — | — | ◇ |
Mark McKenna | ◇ | — | ◇ | — | — | — | ◇ |
Cameron Turtle served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- AnaptysBio, Inc. ANAB
- Apogee Therapeutics, Inc. APGE
- Arcellx, Inc. ACLX
- Astria Therapeutics, Inc. ATXS
- Celldex Therapeutics, Inc. CLDX
- Contineum Therapeutics, Inc. CTNM
- Disc Medicine, Inc. IRON
- Dyne Therapeutics, Inc. DYN
- IGM Biosciences, Inc. IGMS
- Janux Therapeutics, Inc. JANX
- Keros Therapeutics, Inc. KROS
- Kymera Therapeutics, Inc. KYMR
- Nurix Therapeutics, Inc. NRIX
- Pliant Therapeutics, Inc. PLRX
- Stoke Therapeutics, Inc. STOK
- Structure Therapeutics Inc. GPCR
- Vera Therapeutics, Inc. VERA
- Xencor Inc. XNCR
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Cameron Turtle (Chief Executive Officer), FY2025 total compensation $6,707,361 (base salary $665,000) [exec_comp, SEC accession 0001636282-26-000039, filed 2026-04-10]What this page does not include
Everything above is a fact Spyre Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Spyre Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
150 figures on this page, cited to the filing that reported them.
150 cited to the filing
Documents cited
- 0001636282-26-000039EXECUTIVE COMPENSATION TABLES
- 0001636282-24-000021
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Spyre Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SYRE (accessed 2026).
Short form: data: Velarion
The paid brief for Spyre Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Spyre Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Spyre Therapeutics discloses
The companies named in SYRE's own disclosed peer group.
AnaptysBio, Inc.Apogee Therapeutics, Inc.Arcellx, Inc.Astria Therapeutics, Inc.Celldex Therapeutics, Inc.Contineum Therapeutics, Inc.Disc Medicine, Inc.Dyne Therapeutics, Inc.IGM Biosciences, Inc.Janux Therapeutics, Inc.Keros Therapeutics, Inc.Kymera Therapeutics, Inc.Nurix Therapeutics, Inc.Pliant Therapeutics, Inc.Stoke Therapeutics, Inc.Structure Therapeutics Inc.Vera Therapeutics, Inc.Xencor Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}